SENS Sensyne Health Plc

TIDMSENS

RNS Number : 2109F

Sensyne Health PLC

18 March 2022

Sensyne Health plc

("Sensyne" or the "Company")

Issue of New Ordinary Shares and Total Voting Rights

Oxford, U.K. - 18 March 2022: Sensyne Health plc (LSE:SENS) ("Sensyne" or the "Company") today announces that it has issued a total of 1,428,571 new ordinary shares of ten pence nominal value ("New Ordinary Shares").

These New Ordinary Shares have been issued to Great Ormond Street Hospital for Children (GOSH) under the terms of the previously announced strategic research agreements that Sensyne entered into with GOSH on 2 September 2021 and follow the completion of a valuation exercise as required under Section 593 of the Companies Act.

Application has been made to the London Stock Exchange for the admission of the 1,428,571 New Ordinary Shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 21 March 2022.

Total Voting Rights

Following the allotment of the New Ordinary Shares, the total number of ordinary shares following admission will be 166,227,710 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore, following admission the total number of voting rights in Sensyne will be 166,227,710. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-ENDS-

Notes for editors:

About Sensyne Health : https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Contact details:

 
  Sensyne Health 
  Lord (Paul) Drayson PhD FREng, Chief Executive 
   Officer 
   Dr Richard Pye, Chief Financial Officer            +44 (0) 330 058 1845 
  Peel Hunt LLP (Nominated Adviser and Joint          + 44 (0) 20 7418 
   Broker)                                             8900 
  Dr Christopher Golden 
   James Steel 
  Liberum (Joint Broker) 
  Phil Walker                                        + 44 (0) 20 3100 
   William Hall                                       2000 
  Consilium Strategic Communications 
  Mary-Jane Elliott                                  +44 (0) 7780 600290 
   Jessica Hodgson 
   CSCSensynehealth@consilium-comms.com 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFDLLFLXLEBBK

(END) Dow Jones Newswires

March 18, 2022 03:01 ET (07:01 GMT)

Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025

Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025